Endocrine Abstracts

Background: Hypogonadism is associated with cardiometabolic risk. Studies suggest that hypogonadism increases the risk of all-cause and cardiovascular mortality. While some short-term studies have been performed in men with CVD, there are no data on long-term effects of testosterone replacement therapy (TRT) in men with CVD.Methods: In a prospective, cumulative, observational registry study from a single urologist’s office, 300 men with testosterone...

Introduction: Improvements of anthropometric and metabolic parameters on long-term testosterone replacement therapy (TRT) from our registry studies have been reported in 2013 (Saad, Obes; Yassin and Doros, Clin Obes; Traish, Int J Clin Pract).Methods: Five hundred and sixty-one hypogonadal men from both registry studies were divided into age groups ≤65 (Group A, n=450) and >65 years (Group B, n=111). All men were treated with ...

Introduction: Numerous studies have reported inverse associations between testosterone and obesity as well as other components of the metabolic syndrome.Methods: From two registry studies of 561 hypogonadal mens, 46 mens with obesity grade III (BMI ≧40 kg/m2) were selected. All patients received TU injections for up to 6 years. 46 mens were followed for 2 years, 43 for 3 years, 37 for 4 years, 34 for 5 years, and 24 for 6 s. Declining n...

Introduction: Abdominal adipose tissue suppresses testosterone production by various mechanisms affecting the hypothalamic–pituitary–gonadal axis. Hypogonadism leads to further accumulation of fat mass thus creating a vicious circle. This study analysed the effects of restoring testosterone in obese hypogonadal men.Methods: Cumulative, prospective, registry study of 181 men (mean age: 59.11±6.06 years) with testosterone levels below 12.1 n...

Objective: This study investigated effects of testosterone replacement therapy (TRT) on the metabolic syndrome in hypogonadal men over 5 years.Methods: Cumulative, prospective registry study of 164 men with erectile dysfunction and testosterone below 12 nmol/l presenting to a urological institution. All patients received testosterone undecanoate injections 1000 mg every 12 weeks following an initial 6-week interval for a total of 5 years.<p class="ab...